 Prem Subramanian
Concepts (456)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Papilledema | 16 | 2023 | 39 | 6.510 |
Why?
| | Optic Disk | 17 | 2023 | 40 | 5.870 |
Why?
| | Pseudotumor Cerebri | 11 | 2024 | 25 | 4.750 |
Why?
| | Optic Nerve Diseases | 15 | 2023 | 34 | 4.360 |
Why?
| | Intracranial Hypertension | 8 | 2023 | 37 | 4.090 |
Why?
| | Optic Neuropathy, Ischemic | 10 | 2023 | 30 | 4.010 |
Why?
| | Tomography, Optical Coherence | 19 | 2023 | 186 | 3.510 |
Why?
| | Visual Fields | 19 | 2022 | 87 | 3.330 |
Why?
| | Vision Disorders | 18 | 2023 | 135 | 3.260 |
Why?
| | Oculomotor Nerve Diseases | 6 | 2025 | 10 | 2.970 |
Why?
| | Visual Acuity | 19 | 2025 | 321 | 2.930 |
Why?
| | Ophthalmology | 8 | 2024 | 82 | 2.860 |
Why?
| | Eye Injuries | 5 | 2025 | 46 | 2.470 |
Why?
| | Optic Neuritis | 8 | 2023 | 40 | 2.380 |
Why?
| | Abducens Nerve Diseases | 5 | 2022 | 12 | 2.360 |
Why?
| | Hemianopsia | 6 | 2022 | 9 | 2.220 |
Why?
| | Fluorescein Angiography | 10 | 2021 | 143 | 2.050 |
Why?
| | Exophthalmos | 5 | 2024 | 17 | 2.040 |
Why?
| | Retinal Ganglion Cells | 10 | 2022 | 98 | 1.850 |
Why?
| | Carotid-Cavernous Sinus Fistula | 4 | 2021 | 9 | 1.830 |
Why?
| | Nerve Fibers | 9 | 2022 | 89 | 1.770 |
Why?
| | Embolization, Therapeutic | 5 | 2021 | 206 | 1.710 |
Why?
| | Eye Diseases, Hereditary | 3 | 2019 | 11 | 1.690 |
Why?
| | Retinal Artery Occlusion | 2 | 2022 | 8 | 1.560 |
Why?
| | Diplopia | 7 | 2024 | 18 | 1.540 |
Why?
| | Meningioma | 4 | 2023 | 81 | 1.520 |
Why?
| | Graves Ophthalmopathy | 4 | 2024 | 9 | 1.490 |
Why?
| | Eye Diseases | 5 | 2025 | 81 | 1.440 |
Why?
| | Ocular Motility Disorders | 2 | 2023 | 26 | 1.390 |
Why?
| | Intraocular Pressure | 9 | 2022 | 297 | 1.350 |
Why?
| | Humans | 131 | 2025 | 129248 | 1.300 |
Why?
| | Isaacs Syndrome | 2 | 2023 | 5 | 1.280 |
Why?
| | Astronauts | 4 | 2023 | 26 | 1.230 |
Why?
| | Orbit | 6 | 2023 | 57 | 1.210 |
Why?
| | Perceptual Disorders | 2 | 2019 | 22 | 1.190 |
Why?
| | Retina | 5 | 2022 | 277 | 1.160 |
Why?
| | Optic Nerve | 6 | 2023 | 64 | 1.130 |
Why?
| | Space Flight | 4 | 2023 | 80 | 1.090 |
Why?
| | Orbital Diseases | 4 | 2013 | 28 | 1.080 |
Why?
| | Optic Disk Drusen | 4 | 2020 | 6 | 1.060 |
Why?
| | Color Vision Defects | 2 | 2017 | 7 | 1.040 |
Why?
| | Multiple Sclerosis | 3 | 2018 | 436 | 1.010 |
Why?
| | Neurology | 4 | 2021 | 102 | 1.000 |
Why?
| | Trochlear Nerve Diseases | 3 | 2023 | 7 | 1.000 |
Why?
| | Orbital Neoplasms | 2 | 2018 | 21 | 0.950 |
Why?
| | Ophthalmic Artery | 3 | 2021 | 5 | 0.950 |
Why?
| | Academies and Institutes | 2 | 2024 | 49 | 0.920 |
Why?
| | Eye | 3 | 2021 | 104 | 0.890 |
Why?
| | Glaucoma | 6 | 2023 | 219 | 0.880 |
Why?
| | Teratoma | 1 | 2025 | 103 | 0.870 |
Why?
| | Magnetic Resonance Imaging | 13 | 2025 | 3386 | 0.870 |
Why?
| | Rhabdoid Tumor | 1 | 2025 | 95 | 0.860 |
Why?
| | Stroke | 3 | 2017 | 1070 | 0.850 |
Why?
| | Visual Field Tests | 9 | 2020 | 16 | 0.820 |
Why?
| | Optic Atrophy, Hereditary, Leber | 4 | 2024 | 5 | 0.820 |
Why?
| | Intracranial Aneurysm | 2 | 2022 | 95 | 0.810 |
Why?
| | Ophthalmologic Surgical Procedures | 4 | 2018 | 57 | 0.800 |
Why?
| | Orbital Pseudotumor | 2 | 2018 | 3 | 0.800 |
Why?
| | Intracranial Pressure | 5 | 2023 | 45 | 0.770 |
Why?
| | Absorption, Physiological | 1 | 2021 | 4 | 0.770 |
Why?
| | Embolism | 1 | 2022 | 40 | 0.770 |
Why?
| | Prostaglandins, Synthetic | 1 | 2021 | 5 | 0.770 |
Why?
| | Myofibroma | 1 | 2021 | 4 | 0.760 |
Why?
| | Adie Syndrome | 1 | 2021 | 1 | 0.740 |
Why?
| | Neuromyelitis Optica | 1 | 2023 | 129 | 0.740 |
Why?
| | Cerebral Small Vessel Diseases | 1 | 2021 | 4 | 0.740 |
Why?
| | Cerebrospinal Fluid | 1 | 2021 | 91 | 0.730 |
Why?
| | Meningeal Neoplasms | 3 | 2023 | 92 | 0.720 |
Why?
| | Nasal Mucosa | 1 | 2021 | 107 | 0.720 |
Why?
| | Weapons | 1 | 2021 | 8 | 0.720 |
Why?
| | Recreation | 1 | 2021 | 21 | 0.720 |
Why?
| | Civil Disorders | 1 | 2021 | 7 | 0.720 |
Why?
| | Societies, Medical | 2 | 2024 | 744 | 0.710 |
Why?
| | Political Activism | 1 | 2021 | 9 | 0.710 |
Why?
| | Hallucinations | 1 | 2020 | 29 | 0.700 |
Why?
| | Adult | 40 | 2025 | 35495 | 0.690 |
Why?
| | Virtual Reality | 1 | 2021 | 52 | 0.680 |
Why?
| | Glaucoma, Open-Angle | 2 | 2020 | 101 | 0.680 |
Why?
| | Arteriovenous Malformations | 2 | 2011 | 27 | 0.670 |
Why?
| | Male | 52 | 2025 | 63501 | 0.670 |
Why?
| | Peripheral Nerves | 2 | 2020 | 69 | 0.660 |
Why?
| | Middle Aged | 41 | 2025 | 31087 | 0.650 |
Why?
| | Choroid | 1 | 2020 | 62 | 0.650 |
Why?
| | Macula Lutea | 2 | 2019 | 21 | 0.640 |
Why?
| | Cerebrovascular Circulation | 1 | 2021 | 227 | 0.630 |
Why?
| | Regional Blood Flow | 1 | 2021 | 463 | 0.630 |
Why?
| | Vertigo | 1 | 2019 | 38 | 0.620 |
Why?
| | Demyelinating Diseases | 1 | 2019 | 84 | 0.620 |
Why?
| | Optic Nerve Neoplasms | 3 | 2023 | 11 | 0.610 |
Why?
| | Optic Chiasm | 5 | 2021 | 18 | 0.610 |
Why?
| | Female | 50 | 2025 | 68543 | 0.600 |
Why?
| | Sinus Thrombosis, Intracranial | 2 | 2020 | 20 | 0.600 |
Why?
| | Sphenoid Sinus | 1 | 2017 | 10 | 0.580 |
Why?
| | Paranasal Sinus Diseases | 1 | 2017 | 15 | 0.570 |
Why?
| | Reimbursement Mechanisms | 1 | 2018 | 84 | 0.550 |
Why?
| | Cranial Sinuses | 2 | 2014 | 13 | 0.550 |
Why?
| | Contrast Sensitivity | 2 | 2015 | 12 | 0.540 |
Why?
| | Giant Cell Arteritis | 4 | 2022 | 49 | 0.540 |
Why?
| | Postural Balance | 1 | 2019 | 199 | 0.520 |
Why?
| | Aged | 24 | 2025 | 22032 | 0.510 |
Why?
| | Visual Pathways | 2 | 2013 | 50 | 0.510 |
Why?
| | Retinopathy of Prematurity | 3 | 2023 | 141 | 0.500 |
Why?
| | Diagnostic Techniques, Ophthalmological | 3 | 2021 | 38 | 0.490 |
Why?
| | Color Perception Tests | 1 | 2015 | 3 | 0.490 |
Why?
| | Color Vision | 1 | 2015 | 3 | 0.490 |
Why?
| | Arteriovenous Fistula | 2 | 2006 | 35 | 0.490 |
Why?
| | Cerebrospinal Fluid Shunts | 1 | 2015 | 28 | 0.480 |
Why?
| | Carotid Artery, Internal | 3 | 2021 | 41 | 0.480 |
Why?
| | Nervous System Diseases | 3 | 2020 | 252 | 0.470 |
Why?
| | Therapy, Computer-Assisted | 1 | 2015 | 60 | 0.470 |
Why?
| | Recovery of Function | 2 | 2017 | 641 | 0.470 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2020 | 625 | 0.460 |
Why?
| | Head and Neck Neoplasms | 1 | 2020 | 542 | 0.460 |
Why?
| | Aspergillosis | 2 | 2013 | 20 | 0.460 |
Why?
| | Cerebrovascular Disorders | 2 | 2013 | 90 | 0.460 |
Why?
| | Blindness | 2 | 2015 | 38 | 0.450 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 2014 | 34 | 0.450 |
Why?
| | Circle of Willis | 1 | 2013 | 7 | 0.430 |
Why?
| | Young Adult | 18 | 2025 | 12388 | 0.430 |
Why?
| | Headache | 5 | 2021 | 151 | 0.430 |
Why?
| | Medical Audit | 1 | 2013 | 74 | 0.430 |
Why?
| | Decompression, Surgical | 1 | 2014 | 95 | 0.430 |
Why?
| | Endarterectomy, Carotid | 1 | 2013 | 47 | 0.430 |
Why?
| | Brain Injuries, Traumatic | 1 | 2018 | 341 | 0.430 |
Why?
| | Ischemic Attack, Transient | 1 | 2013 | 60 | 0.410 |
Why?
| | Medicare | 1 | 2018 | 706 | 0.400 |
Why?
| | Ophthalmologists | 2 | 2024 | 11 | 0.400 |
Why?
| | Ubiquinone | 2 | 2024 | 28 | 0.400 |
Why?
| | Cerebral Angiography | 4 | 2021 | 108 | 0.400 |
Why?
| | Referral and Consultation | 1 | 2018 | 727 | 0.390 |
Why?
| | Skin Neoplasms | 1 | 2020 | 824 | 0.390 |
Why?
| | Retrospective Studies | 18 | 2023 | 14455 | 0.380 |
Why?
| | Lymphangioma | 1 | 2011 | 7 | 0.380 |
Why?
| | Varicose Veins | 1 | 2011 | 17 | 0.370 |
Why?
| | Diagnosis, Differential | 4 | 2023 | 1430 | 0.370 |
Why?
| | Follow-Up Studies | 8 | 2024 | 4886 | 0.360 |
Why?
| | Oculomotor Muscles | 2 | 2023 | 38 | 0.360 |
Why?
| | Eye Infections, Fungal | 1 | 2010 | 7 | 0.350 |
Why?
| | Aspergillus fumigatus | 1 | 2010 | 23 | 0.350 |
Why?
| | Brain Diseases | 1 | 2011 | 136 | 0.340 |
Why?
| | Algorithms | 6 | 2023 | 1613 | 0.330 |
Why?
| | Military Medicine | 2 | 2008 | 62 | 0.330 |
Why?
| | ROC Curve | 6 | 2021 | 502 | 0.330 |
Why?
| | Cross-Sectional Studies | 7 | 2023 | 5045 | 0.320 |
Why?
| | Practice Patterns, Physicians' | 2 | 2018 | 1267 | 0.310 |
Why?
| | Retinal Vein | 1 | 2008 | 13 | 0.300 |
Why?
| | United States | 10 | 2024 | 13828 | 0.300 |
Why?
| | Cerebrospinal Fluid Proteins | 1 | 2008 | 8 | 0.300 |
Why?
| | Diabetes Mellitus | 1 | 2016 | 1000 | 0.300 |
Why?
| | Strabismus | 1 | 2008 | 28 | 0.290 |
Why?
| | Iraq War, 2003-2011 | 1 | 2008 | 123 | 0.290 |
Why?
| | Postoperative Complications | 3 | 2013 | 2473 | 0.290 |
Why?
| | Eye Movements | 2 | 2018 | 59 | 0.280 |
Why?
| | Corneal Edema | 1 | 2007 | 4 | 0.280 |
Why?
| | Eye Pain | 2 | 2017 | 7 | 0.280 |
Why?
| | Ophthalmoplegia, Chronic Progressive External | 1 | 2007 | 3 | 0.280 |
Why?
| | Mitochondrial Myopathies | 1 | 2007 | 8 | 0.280 |
Why?
| | Prostatectomy | 1 | 2007 | 106 | 0.280 |
Why?
| | Astigmatism | 2 | 2006 | 10 | 0.270 |
Why?
| | Brain | 3 | 2021 | 2669 | 0.270 |
Why?
| | Photorefractive Keratectomy | 2 | 2006 | 19 | 0.270 |
Why?
| | Septo-Optic Dysplasia | 1 | 2006 | 4 | 0.270 |
Why?
| | Stents | 3 | 2016 | 502 | 0.260 |
Why?
| | Craniocerebral Trauma | 1 | 2008 | 151 | 0.260 |
Why?
| | Temporal Arteries | 3 | 2022 | 45 | 0.260 |
Why?
| | Cavernous Sinus | 2 | 2021 | 17 | 0.250 |
Why?
| | Visual Cortex | 1 | 2006 | 68 | 0.250 |
Why?
| | Ophthalmoscopy | 3 | 2021 | 35 | 0.250 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2008 | 247 | 0.250 |
Why?
| | Carotid Artery Diseases | 1 | 2005 | 64 | 0.240 |
Why?
| | Prospective Studies | 9 | 2019 | 7121 | 0.240 |
Why?
| | Transverse Sinuses | 2 | 2016 | 8 | 0.240 |
Why?
| | Ocular Hypertension | 3 | 2015 | 66 | 0.240 |
Why?
| | Adolescent | 12 | 2025 | 20303 | 0.230 |
Why?
| | Retinal Artery | 1 | 2004 | 16 | 0.230 |
Why?
| | Retinitis | 1 | 2004 | 19 | 0.230 |
Why?
| | Craniotomy | 1 | 2025 | 67 | 0.230 |
Why?
| | Retinal Vasculitis | 1 | 2004 | 10 | 0.230 |
Why?
| | Peptide Hormones | 1 | 2004 | 11 | 0.230 |
Why?
| | Aneurysm | 1 | 2004 | 30 | 0.230 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2024 | 758 | 0.230 |
Why?
| | Fatal Outcome | 1 | 2025 | 299 | 0.220 |
Why?
| | Eyelids | 1 | 2024 | 34 | 0.220 |
Why?
| | Laser Coagulation | 2 | 2019 | 57 | 0.210 |
Why?
| | Ultrasonography | 2 | 2021 | 713 | 0.210 |
Why?
| | Eyeglasses | 1 | 2003 | 5 | 0.210 |
Why?
| | Diphosphonates | 1 | 2003 | 58 | 0.210 |
Why?
| | Substance Abuse Detection | 1 | 2024 | 79 | 0.210 |
Why?
| | Parvovirinae | 1 | 2022 | 2 | 0.210 |
Why?
| | Physicians | 2 | 2022 | 859 | 0.200 |
Why?
| | Eye Burns | 1 | 2022 | 12 | 0.200 |
Why?
| | Radiation Injuries | 1 | 2004 | 135 | 0.200 |
Why?
| | Paralysis | 1 | 2023 | 69 | 0.200 |
Why?
| | Compartment Syndromes | 1 | 2022 | 22 | 0.200 |
Why?
| | Eyelid Diseases | 1 | 2022 | 18 | 0.200 |
Why?
| | Arteries | 2 | 2021 | 265 | 0.200 |
Why?
| | Myopia | 1 | 2003 | 47 | 0.200 |
Why?
| | Cornea | 1 | 2003 | 128 | 0.190 |
Why?
| | Fluorometry | 1 | 2021 | 17 | 0.190 |
Why?
| | Weight Loss | 2 | 2024 | 732 | 0.190 |
Why?
| | Oculomotor Nerve | 1 | 2021 | 5 | 0.190 |
Why?
| | Hallucinogens | 1 | 2024 | 102 | 0.190 |
Why?
| | Fundus Oculi | 2 | 2020 | 61 | 0.190 |
Why?
| | Dinoprost | 1 | 2021 | 44 | 0.190 |
Why?
| | Administration, Intranasal | 1 | 2021 | 84 | 0.190 |
Why?
| | Treatment Outcome | 9 | 2024 | 10199 | 0.190 |
Why?
| | Skull Base | 1 | 2021 | 45 | 0.190 |
Why?
| | Endovascular Procedures | 2 | 2018 | 301 | 0.190 |
Why?
| | Wounds and Injuries | 1 | 2008 | 710 | 0.180 |
Why?
| | Blood Pressure | 1 | 2008 | 1736 | 0.180 |
Why?
| | Aged, 80 and over | 5 | 2017 | 7055 | 0.180 |
Why?
| | Retinal Vessels | 1 | 2021 | 65 | 0.180 |
Why?
| | Dissent and Disputes | 1 | 2021 | 17 | 0.180 |
Why?
| | Marijuana Abuse | 1 | 2024 | 233 | 0.180 |
Why?
| | Bariatric Surgery | 1 | 2024 | 193 | 0.180 |
Why?
| | Posture | 2 | 2019 | 175 | 0.180 |
Why?
| | Bone Neoplasms | 1 | 2003 | 231 | 0.180 |
Why?
| | Risk Factors | 7 | 2025 | 9745 | 0.180 |
Why?
| | Lewy Bodies | 1 | 2020 | 10 | 0.180 |
Why?
| | Crowding | 1 | 2021 | 35 | 0.180 |
Why?
| | Antigens, Viral | 1 | 2021 | 178 | 0.170 |
Why?
| | Vision, Ocular | 1 | 2020 | 35 | 0.170 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 112 | 0.170 |
Why?
| | Macular Degeneration | 1 | 2022 | 159 | 0.170 |
Why?
| | Fluorescent Dyes | 1 | 2021 | 312 | 0.170 |
Why?
| | Prostatic Neoplasms | 2 | 2007 | 1016 | 0.170 |
Why?
| | Fovea Centralis | 1 | 2019 | 11 | 0.160 |
Why?
| | Congresses as Topic | 1 | 2021 | 216 | 0.160 |
Why?
| | Neurosurgical Procedures | 2 | 2018 | 166 | 0.160 |
Why?
| | DNA, Viral | 1 | 2021 | 349 | 0.160 |
Why?
| | Microvessels | 1 | 2020 | 82 | 0.160 |
Why?
| | Sensitivity and Specificity | 4 | 2022 | 1837 | 0.160 |
Why?
| | Child | 8 | 2025 | 20773 | 0.150 |
Why?
| | Retinal Detachment | 1 | 2019 | 56 | 0.150 |
Why?
| | Inflammation | 4 | 2023 | 2737 | 0.150 |
Why?
| | Health Surveys | 1 | 2021 | 493 | 0.150 |
Why?
| | Ligation | 1 | 2018 | 87 | 0.150 |
Why?
| | Tonometry, Ocular | 3 | 2019 | 88 | 0.150 |
Why?
| | Dizziness | 1 | 2019 | 80 | 0.150 |
Why?
| | Skull Base Neoplasms | 1 | 2018 | 25 | 0.150 |
Why?
| | Infant | 6 | 2025 | 8975 | 0.150 |
Why?
| | Forms and Records Control | 1 | 2018 | 22 | 0.150 |
Why?
| | Quality of Life | 4 | 2022 | 2685 | 0.150 |
Why?
| | Healthy Volunteers | 1 | 2019 | 200 | 0.150 |
Why?
| | Transcranial Direct Current Stimulation | 1 | 2017 | 4 | 0.140 |
Why?
| | Herpesvirus 3, Human | 1 | 2021 | 331 | 0.140 |
Why?
| | Angiogenesis Inhibitors | 1 | 2019 | 220 | 0.140 |
Why?
| | Social Media | 1 | 2020 | 137 | 0.140 |
Why?
| | Periodicals as Topic | 1 | 2020 | 204 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 248 | 0.140 |
Why?
| | Child, Preschool | 3 | 2025 | 10456 | 0.140 |
Why?
| | Capillaries | 1 | 2018 | 103 | 0.140 |
Why?
| | Headache Disorders | 1 | 2017 | 17 | 0.140 |
Why?
| | Hypoxanthine Phosphoribosyltransferase | 1 | 1997 | 25 | 0.140 |
Why?
| | Disease Progression | 3 | 2020 | 2630 | 0.140 |
Why?
| | X Chromosome | 1 | 1997 | 52 | 0.140 |
Why?
| | Accidents, Traffic | 1 | 2018 | 184 | 0.130 |
Why?
| | Arteritis | 1 | 2016 | 26 | 0.130 |
Why?
| | Prevalence | 2 | 2016 | 2554 | 0.130 |
Why?
| | Area Under Curve | 2 | 2014 | 304 | 0.130 |
Why?
| | Reproducibility of Results | 3 | 2024 | 3079 | 0.130 |
Why?
| | Education, Medical, Graduate | 1 | 2020 | 438 | 0.130 |
Why?
| | Constriction, Pathologic | 2 | 2014 | 226 | 0.130 |
Why?
| | Abducens Nerve | 1 | 2015 | 3 | 0.130 |
Why?
| | Burnout, Professional | 1 | 2022 | 404 | 0.130 |
Why?
| | Activities of Daily Living | 1 | 2019 | 381 | 0.120 |
Why?
| | Neuronal Plasticity | 2 | 2017 | 279 | 0.120 |
Why?
| | Pandemics | 2 | 2022 | 1482 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 339 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 333 | 0.120 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2020 | 742 | 0.120 |
Why?
| | Autoantibodies | 1 | 2023 | 1467 | 0.120 |
Why?
| | DNA Replication | 1 | 1997 | 227 | 0.120 |
Why?
| | Lateral Sinus Thrombosis | 1 | 2015 | 1 | 0.120 |
Why?
| | Machine Learning | 1 | 2020 | 442 | 0.120 |
Why?
| | Animals | 5 | 2021 | 35307 | 0.120 |
Why?
| | Myocardial Ischemia | 1 | 2016 | 258 | 0.120 |
Why?
| | Recurrence | 1 | 2018 | 1005 | 0.120 |
Why?
| | Health Policy | 1 | 2018 | 351 | 0.120 |
Why?
| | Melanoma | 1 | 2021 | 729 | 0.120 |
Why?
| | Telemedicine | 1 | 2023 | 789 | 0.110 |
Why?
| | Gestational Age | 3 | 2023 | 874 | 0.110 |
Why?
| | Case-Control Studies | 2 | 2016 | 3377 | 0.110 |
Why?
| | Syndrome | 3 | 2019 | 339 | 0.110 |
Why?
| | Carbamazepine | 1 | 2013 | 19 | 0.110 |
Why?
| | Practice Guidelines as Topic | 1 | 2021 | 1497 | 0.100 |
Why?
| | Incidence | 3 | 2022 | 2636 | 0.100 |
Why?
| | Abscess | 1 | 2013 | 73 | 0.100 |
Why?
| | Cognition | 1 | 2020 | 1122 | 0.100 |
Why?
| | Dependovirus | 2 | 2023 | 62 | 0.100 |
Why?
| | Antineoplastic Agents | 1 | 2003 | 2053 | 0.100 |
Why?
| | Carotid Artery, Internal, Dissection | 1 | 2012 | 13 | 0.100 |
Why?
| | Imaging, Three-Dimensional | 1 | 2015 | 529 | 0.100 |
Why?
| | Hemodynamics | 1 | 2016 | 1090 | 0.090 |
Why?
| | Vision, Binocular | 1 | 2011 | 17 | 0.090 |
Why?
| | Predictive Value of Tests | 2 | 2014 | 1946 | 0.090 |
Why?
| | Anticonvulsants | 1 | 2013 | 209 | 0.090 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5439 | 0.090 |
Why?
| | Neonatal Screening | 2 | 2023 | 163 | 0.090 |
Why?
| | Obesity | 1 | 2004 | 2879 | 0.090 |
Why?
| | Penicillin G Benzathine | 1 | 2010 | 1 | 0.090 |
Why?
| | DNA Transposable Elements | 1 | 1992 | 118 | 0.090 |
Why?
| | Syphilis Serodiagnosis | 1 | 2010 | 4 | 0.090 |
Why?
| | Penicillin G | 1 | 2010 | 7 | 0.090 |
Why?
| | Genetic Therapy | 2 | 2023 | 288 | 0.090 |
Why?
| | Psychology | 1 | 2011 | 82 | 0.090 |
Why?
| | Military Personnel | 2 | 2008 | 515 | 0.090 |
Why?
| | Combined Modality Therapy | 1 | 2013 | 1199 | 0.090 |
Why?
| | Histoplasmosis | 1 | 2010 | 14 | 0.080 |
Why?
| | Time Factors | 5 | 2020 | 6543 | 0.080 |
Why?
| | Artificial Intelligence | 2 | 2023 | 246 | 0.080 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2010 | 135 | 0.080 |
Why?
| | Venous Pressure | 1 | 2008 | 8 | 0.080 |
Why?
| | Polymerase Chain Reaction | 1 | 1992 | 1036 | 0.080 |
Why?
| | Antioxidants | 2 | 2024 | 558 | 0.080 |
Why?
| | Iraq | 1 | 2008 | 52 | 0.070 |
Why?
| | Afghanistan | 1 | 2008 | 70 | 0.070 |
Why?
| | Birth Weight | 2 | 2023 | 505 | 0.070 |
Why?
| | Escherichia coli | 1 | 1992 | 766 | 0.070 |
Why?
| | Drug Therapy, Combination | 1 | 2010 | 1040 | 0.070 |
Why?
| | Cohort Studies | 2 | 2016 | 5408 | 0.070 |
Why?
| | Disease Models, Animal | 1 | 2017 | 4057 | 0.070 |
Why?
| | Lasers, Excimer | 2 | 2006 | 29 | 0.070 |
Why?
| | Darkness | 1 | 2006 | 25 | 0.060 |
Why?
| | Infant, Newborn | 3 | 2023 | 5736 | 0.060 |
Why?
| | Keratomileusis, Laser In Situ | 1 | 2006 | 22 | 0.060 |
Why?
| | Functional Laterality | 1 | 2006 | 222 | 0.060 |
Why?
| | Maxillary Artery | 1 | 2005 | 3 | 0.060 |
Why?
| | Developed Countries | 1 | 2025 | 34 | 0.060 |
Why?
| | Prognosis | 1 | 2013 | 3772 | 0.060 |
Why?
| | Angiography, Digital Subtraction | 1 | 2005 | 43 | 0.060 |
Why?
| | Growth Cones | 1 | 2004 | 7 | 0.060 |
Why?
| | Bucladesine | 1 | 2004 | 25 | 0.060 |
Why?
| | Mice | 1 | 2021 | 16915 | 0.060 |
Why?
| | Retinal Hemorrhage | 1 | 2004 | 19 | 0.060 |
Why?
| | Platinum | 1 | 2005 | 44 | 0.060 |
Why?
| | Veins | 1 | 2005 | 60 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 2 | 2013 | 2515 | 0.060 |
Why?
| | Body Constitution | 1 | 2004 | 53 | 0.060 |
Why?
| | Ghrelin | 1 | 2004 | 32 | 0.060 |
Why?
| | Nerve Regeneration | 1 | 2004 | 62 | 0.060 |
Why?
| | Ganglia, Spinal | 1 | 2004 | 75 | 0.060 |
Why?
| | Brain Neoplasms | 1 | 2013 | 1143 | 0.060 |
Why?
| | Receptor, IGF Type 1 | 1 | 2024 | 65 | 0.060 |
Why?
| | Growth Hormone | 1 | 2004 | 96 | 0.060 |
Why?
| | Stereotaxic Techniques | 1 | 2004 | 37 | 0.060 |
Why?
| | Delphi Technique | 1 | 2025 | 225 | 0.050 |
Why?
| | Tremor | 1 | 2024 | 60 | 0.050 |
Why?
| | Psychomotor Performance | 1 | 2006 | 313 | 0.050 |
Why?
| | Tubulin | 1 | 2004 | 137 | 0.050 |
Why?
| | Demography | 1 | 2024 | 279 | 0.050 |
Why?
| | Equipment Design | 1 | 2005 | 513 | 0.050 |
Why?
| | Leptin | 1 | 2004 | 219 | 0.050 |
Why?
| | Magnetic Resonance Angiography | 1 | 2005 | 234 | 0.050 |
Why?
| | Angiography | 1 | 2023 | 196 | 0.050 |
Why?
| | Prednisone | 1 | 2003 | 233 | 0.050 |
Why?
| | Mutation | 2 | 2024 | 3710 | 0.050 |
Why?
| | Baltimore | 2 | 2012 | 45 | 0.050 |
Why?
| | Global Health | 1 | 2025 | 327 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 615 | 0.050 |
Why?
| | Methylprednisolone | 1 | 2022 | 83 | 0.050 |
Why?
| | DNA, Mitochondrial | 1 | 2023 | 191 | 0.050 |
Why?
| | Tissue Fixation | 1 | 2021 | 34 | 0.050 |
Why?
| | Paraffin Embedding | 1 | 2021 | 29 | 0.050 |
Why?
| | CTLA-4 Antigen | 1 | 2021 | 87 | 0.050 |
Why?
| | Genetic Vectors | 1 | 2022 | 312 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2023 | 373 | 0.050 |
Why?
| | Formaldehyde | 1 | 2021 | 60 | 0.050 |
Why?
| | Spinal Cord Injuries | 1 | 2004 | 194 | 0.050 |
Why?
| | Safety | 1 | 2003 | 330 | 0.040 |
Why?
| | Anti-Bacterial Agents | 1 | 2010 | 1702 | 0.040 |
Why?
| | Marijuana Smoking | 1 | 2024 | 247 | 0.040 |
Why?
| | Myasthenia Gravis | 1 | 2020 | 21 | 0.040 |
Why?
| | Light | 1 | 2003 | 359 | 0.040 |
Why?
| | Firearms | 1 | 2006 | 359 | 0.040 |
Why?
| | Tertiary Prevention | 1 | 2019 | 3 | 0.040 |
Why?
| | Axial Length, Eye | 1 | 2019 | 15 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2003 | 480 | 0.040 |
Why?
| | Immunomodulation | 1 | 2020 | 92 | 0.040 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2021 | 232 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2021 | 195 | 0.040 |
Why?
| | Intravitreal Injections | 1 | 2019 | 56 | 0.040 |
Why?
| | Extraterrestrial Environment | 1 | 2019 | 12 | 0.040 |
Why?
| | India | 1 | 2019 | 170 | 0.040 |
Why?
| | Academic Medical Centers | 2 | 2012 | 474 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 5382 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 428 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2023 | 1875 | 0.040 |
Why?
| | Gravity, Altered | 1 | 2018 | 7 | 0.040 |
Why?
| | Centrifugation | 1 | 2018 | 30 | 0.040 |
Why?
| | Secondary Prevention | 1 | 2019 | 218 | 0.040 |
Why?
| | Blood Loss, Surgical | 1 | 2018 | 93 | 0.040 |
Why?
| | Rotation | 1 | 2018 | 111 | 0.040 |
Why?
| | Primary Prevention | 1 | 2019 | 188 | 0.040 |
Why?
| | Protein Kinase Inhibitors | 1 | 2023 | 890 | 0.040 |
Why?
| | Acetazolamide | 1 | 2017 | 24 | 0.040 |
Why?
| | Hybrid Cells | 1 | 1997 | 50 | 0.030 |
Why?
| | Diuretics | 1 | 2017 | 75 | 0.030 |
Why?
| | Cannabis | 1 | 2024 | 463 | 0.030 |
Why?
| | Cell Line, Transformed | 1 | 1997 | 140 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2019 | 530 | 0.030 |
Why?
| | Cricetinae | 1 | 1997 | 278 | 0.030 |
Why?
| | Weight Reduction Programs | 1 | 2017 | 110 | 0.030 |
Why?
| | Cloning, Molecular | 1 | 1997 | 525 | 0.030 |
Why?
| | Body Mass Index | 1 | 2004 | 2272 | 0.030 |
Why?
| | Azacitidine | 1 | 1997 | 139 | 0.030 |
Why?
| | Analgesics | 1 | 2017 | 189 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2017 | 284 | 0.030 |
Why?
| | Treatment Failure | 1 | 2016 | 339 | 0.030 |
Why?
| | Sex Distribution | 1 | 2016 | 359 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 854 | 0.030 |
Why?
| | Infant, Premature | 1 | 2019 | 541 | 0.030 |
Why?
| | Enzyme Activation | 1 | 1997 | 812 | 0.030 |
Why?
| | Vision Tests | 1 | 2015 | 16 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1688 | 0.030 |
Why?
| | Heart Rate | 1 | 2018 | 802 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2014 | 114 | 0.030 |
Why?
| | Insulin | 1 | 2004 | 2325 | 0.030 |
Why?
| | Itraconazole | 1 | 2013 | 6 | 0.030 |
Why?
| | Tinnitus | 1 | 2015 | 57 | 0.030 |
Why?
| | Immunocompetence | 1 | 2013 | 43 | 0.030 |
Why?
| | Voriconazole | 1 | 2013 | 20 | 0.030 |
Why?
| | Vaccination | 1 | 2022 | 1347 | 0.030 |
Why?
| | Chromatin | 1 | 1997 | 478 | 0.030 |
Why?
| | Debridement | 1 | 2013 | 83 | 0.030 |
Why?
| | Antifungal Agents | 1 | 2013 | 129 | 0.030 |
Why?
| | Gene Expression Regulation | 2 | 2004 | 2537 | 0.020 |
Why?
| | Disease Management | 1 | 2016 | 588 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1544 | 0.020 |
Why?
| | Hypercholesterolemia | 1 | 2013 | 102 | 0.020 |
Why?
| | DNA Probes | 1 | 1992 | 61 | 0.020 |
Why?
| | Triazoles | 1 | 2013 | 148 | 0.020 |
Why?
| | Mutagenesis, Insertional | 1 | 1992 | 65 | 0.020 |
Why?
| | Neurosurgery | 1 | 2012 | 35 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1992 | 173 | 0.020 |
Why?
| | Diabetes Complications | 1 | 2013 | 224 | 0.020 |
Why?
| | Neuroimaging | 1 | 2013 | 278 | 0.020 |
Why?
| | History, 20th Century | 1 | 2012 | 291 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 1992 | 385 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 1992 | 504 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 1992 | 321 | 0.020 |
Why?
| | Acute Disease | 1 | 2013 | 978 | 0.020 |
Why?
| | Pyrimidines | 1 | 2013 | 459 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1691 | 0.020 |
Why?
| | Base Sequence | 1 | 1992 | 2146 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 1992 | 2835 | 0.020 |
Why?
| | Coronary Artery Disease | 1 | 2013 | 679 | 0.020 |
Why?
| | Postoperative Period | 1 | 2006 | 329 | 0.010 |
Why?
| | Tissue Transplantation | 1 | 2004 | 10 | 0.010 |
Why?
| | Growth Inhibitors | 1 | 2004 | 44 | 0.010 |
Why?
| | Axonal Transport | 1 | 2004 | 26 | 0.010 |
Why?
| | Visual Perception | 1 | 2006 | 162 | 0.010 |
Why?
| | Hypertension | 1 | 2013 | 1242 | 0.010 |
Why?
| | Up-Regulation | 1 | 2004 | 839 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 2396 | 0.010 |
Why?
| | Rats | 1 | 2004 | 5482 | 0.010 |
Why?
|
|
Subramanian's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|